Folkert H. M. Morsink

Folkert H. M. Morsink

Auto-generated profile, based on publicly available information

Folkert H. M. Morsink

Department of Pathology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
EDElse Driehuis
Else Driehuis
AHArne van Hoeck
Arne van Hoeck
KMKat Moore
Kat Moore
SKSigrid Kolders
Sigrid Kolders
HFHayley E. Francies
Hayley E. Francies
Hans CleversHans Clevers
Hans Clevers
We report the derivation of 30 patient-derived organoid lines (PDOs) from tumors arising in the pancreas and distal bile duct. PDOs recapitulate tumor histology and contain genetic alterations typical of pancreatic cancer. In vitro testing of a panel of 76 therapeutic agents revealed sensitivities currently not exploited in the clinic, and underscores the importance of personalized approaches for effective cancer treatment. The PRMT5 inhibitor EZP015556, shown to target MTAP (a gene commonly lost in pancreatic cancer)-negative tumors, was validated as such, but also appeared to constitute an effective therapy for a subset of MTAP-positive tumors. Taken together, the work presented here provides a platform to identify novel therapeutics to target pancreatic tumor cells using PDOs.

20 March 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
WHWilma H. M. Hoevenaar
Wilma H. M. Hoevenaar
AJAniek Janssen
Aniek Janssen
AQAjit I. Quirindongo
Ajit I. Quirindongo
HMHuiying Ma
Huiying Ma
SKSjoerd J. Klaasen
Sjoerd J. Klaasen
NJNannette Jelluma
Nannette Jelluma
Most human cancers are aneuploid, due to a chromosomal instability (CIN) phenotype. Despite being hallmarks of cancer, however, the roles of CIN and aneuploidy in tumor formation have not unequivocally emerged from animal studies and are thus still unclear. Using a conditional mouse model for diverse degrees of CIN, we find that a particular range is sufficient to drive very early onset spontaneous adenoma formation in the intestine. In mice predisposed to intestinal cancer (ApcMin/+), moderate CIN causes a remarkable increase in adenoma burden in the entire intestinal tract and especially in the distal colon, which resembles human disease. Strikingly, a higher level of CIN promotes adenoma formation in the distal colon even more than moderate CIN does, but has no effect in the small intestine. Our results thus show that CIN can be potently oncogenic, but that certain levels of CIN can have contrasting effects in distinct tissues.

1 March 2021 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
WHWenzel M. Hackeng
Wenzel M. Hackeng
KDKoen M.A. Dreijerink
Koen M.A. Dreijerink
WLWendy W.J. de Leng
Wendy W.J. de Leng
FMFolkert H.M. Morsink
Folkert H.M. Morsink
GVGerlof D. Valk
Gerlof D. Valk
LBLodewijk A. A. Brosens
Lodewijk A. A. Brosens
Purpose: The primary origin of neuroendocrine tumor metastases can be difficult to determine by histopathology alone, but is critical for therapeutic decision making. DNA methylation–based profiling is now routinely used in the diagnostic workup of brain tumors. This has been enabled by the availability of cost-efficient array-based platforms. We have extended these efforts to augment histopathologic diagnosis in neuroendocrine tumors. Experimental Design: Methylation data was compiled for 69 small intestinal, pulmonary, and pancreatic neuroendocrine tumors. These data were used to build a ridge regression calibrated random forest classification algorithm (neuroendocrine neoplasm identifier, NEN-ID). The model was validated during 3 × 3 nested cross-validation and tested in a local and an external cohort (n = 198 cases). Results: NEN-ID predicted the origin of tumor samples with high accuracy (>95%). In addition, the diagnostic approach was determined to be robust across a range of possible confounding experimental parameters, such as tumor purity and array quality. A software infrastructure and online user interface were built to make the model available to the scientific community. Conclusions: This DNA methylation–based prediction model can be used in the workup for patients with neuroendocrine tumors of unknown primary. To facilitate validation and clinical implementation, we provide a user-friendly, publicly available web-based version of NEN-ID.

20 August 2020 in Molecular and Clinical Oncology
Verified
Journal Article
Open access
PDF file
MSMalgorzata Szlendak
Malgorzata Szlendak
RSRobert Sitarz
Robert Sitarz
MBMonika Berbecka
Monika Berbecka
JMJerzy Mielko
Jerzy Mielko
FMFolkert Morsink
Folkert Morsink
Wojciech PolkowskiWojciech Polkowski
Wojciech Polkowski
In colorectal cancer (CRC), pathological factors that correlate with negative prognosis include, among others, overexpression of cyclooxygenase‑2 (COX‑2) and abundant expression of mucin 1 (MUC1). COX‑2 overexpression may therefore be associated with MUC1 overexpression. The aim of the present study was to investigate the possible correlation between COX‑2 and MUC1 expression and to assess the correlation between their individual expression and the clinicopathological features of patients, paying particular attention to survival. The following data was collected from the 170 patients with CRC included in the present study: Age, sex, tumour localization, disease stage and survival. Tumour samples were immunostained with antibodies against COX‑2 and MUC1. Protein expression was scored, relative to reference staining, and correlated with the clinicopathological data of patients. The results revealed no correlation between the expressions of COX‑2 and MUC1, or with any of the studied clinicopathological variables. In addition, the expression of the two proteins were not associated. Neither of the proteins demonstrated prognostic value for survival. The present study did not confirm a direct relationship between the expressions of COX‑2 and MUC1, or between the expression of either protein and the clinicopathological features of patients, including survival.

31 March 2023
Verified
Other
Open access
WHWenzel M. Hackeng
Wenzel M. Hackeng
KDKoen M.A. Dreijerink
Koen M.A. Dreijerink
WLWendy W.J. de Leng
Wendy W.J. de Leng
FMFolkert H.M. Morsink
Folkert H.M. Morsink
GVGerlof D. Valk
Gerlof D. Valk
LBLodewijk A. A. Brosens
Lodewijk A. A. Brosens

31 March 2023
Verified
Other
Open access
WHWenzel M. Hackeng
Wenzel M. Hackeng
KDKoen M.A. Dreijerink
Koen M.A. Dreijerink
WLWendy W.J. de Leng
Wendy W.J. de Leng
FMFolkert H.M. Morsink
Folkert H.M. Morsink
GVGerlof D. Valk
Gerlof D. Valk
LBLodewijk A. A. Brosens
Lodewijk A. A. Brosens
NEN-ID local and external cohort scores